dabigatran etexilate / Generic mfg. - LARVOL DELTA

Trends in Antithrombotic Therapy Initiation Among Patients With Stroke Pre- and Post-COVID-19 in Sweden-An Interrupted Time Series Study. (PubMed, Basic Clin Pharmacol Toxicol) - "The COVID-19 pandemic had no impact on the overall use of antithrombotic agents. However, a short-term increase in antiplatelet initiation and long-term changes in warfarin, dabigatran, and factor Xa initiations were observed after the COVID-19 outbreak."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

A Chromatographic Approach for Simultaneous Quantification of Multiple Anticoagulants in Human Plasma Samples. (PubMed, J Sep Sci) - "In this context, the present study aimed to develop an HPLC method with UV/Vis detection for the simultaneous quantification of four anticoagulant agents (warfarin, dabigatran, rivaroxaban, and apixaban) in human plasma. Stability testing demonstrated that all analytes remained stable at room temperature for 24 h, with only dabigatran showing reduced stability after three freeze-thaw cycles. The proposed method enabled rapid and simultaneous quantification of four clinically relevant anticoagulants in plasma samples."

Journal • Cardiovascular • Nephrology • Renal Disease • Thrombosis

Carrageenan: A Non-mammalian Allergen in Alpha-gal Syndrome (AAAAI 2026) - "Carrageenan, an additive in food (e.g. select manufacturers of chocolate milk, tofu), and medications (e.g. select manufacturers of acetaminophen, dabigatran etexilate capsules, omeprazole) is a sulfated polysaccharide from red algae that can also contain the alpha-gal epitope. Conclusions Carrageenan is a frequently reported allergen in AGS patients and the mechanism needs elucidation. Patients sensitive to alpha-gal in medications should particularly be questioned and counseled on a potential reaction to carrageenan."

Food Hypersensitivity • Immunology

Thrombotic and Hemorrhagic Adverse Events of Direct Oral Anticoagulants: An Analysis of Sex-Related Differences Using Food and Drug Administration Adverse Event Reporting System. (PubMed, Anatol J Cardiol) - "Significant sex-specific differences exist in DOAC safety profiles. Recognizing these patterns may inform individualized anticoagulant selection and enhance pharmacovigilance-driven personalized medicine."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases

Impact of DOAC plasma levels on hematoma expansion in DOAC-associated intracerebral hemorrhage: a preliminary multicenter analysis (ISC 2026) - "Most received FXa inhibitors (98%), four dabigatran (median DOAC level: 101.5 ng/mL [IQR 51–187.5])... The risk of symptomatic HE may increase with higher DOAC plasma levels in patients with DOAC-associated ICH, with a possible threshold effect at very high levels. These preliminary findings require further analysis of the full multicenter cohort to assess the predictive value of specific DOAC thresholds for clinical risk stratification."

Clinical • Cerebral Hemorrhage • Hematological Disorders

Refining Embolic Stroke of Undetermined Source (ESUS) Management: A Systematic Synthesis of Diagnostic and Therapeutic Advances (ISC 2026) - "An exploratory NAVIGATE ESUS analysis showed rivaroxaban reduced recurrent stroke vs.aspirin in this group...NAVIGATE ESUS showed a 74% stroke reduction with rivaroxaban in patients with LA diameter >46 mm, underscoring the need to refine AC selection markers.3.RE-SPECT ESUS linked NT-proBNP >505 pg/mL and older age to higher AFib incidence, with age >75 benefiting from low-dose dabigatran...This approach necessitates individualized risk assessment.CONCLUSION Despite antiplatelets remaining the standard for secondary prevention, ESUS carries a 5% annual recurrence. This review underscores a need to move beyond a uniform approach—highlighting how emerging biomarkers, imaging modalities, and targeted anticoagulation strategies could help individualize stroke prevention in specific ESUS population."

Atherosclerosis • Cardiovascular • Ischemic stroke • Thrombosis

DOAC Pharmacologic Interactions in Acute Ischemic/TIA vs Hemorrhagic Stroke: Findings from a 77-Hospital Telestroke Program (ISC 2026) - "DOAC distribution: rivaroxaban 314/446 (70.4%) , apixaban 101/446 (22.6%) , edoxaban 17/446 (3.8%) , dabigatran 14/446 (3.1%) . Cerebrovascular presentations: ischemic stroke 381/446 (85.4%) , non-SAH hemorrhagic stroke 41/446 (9.2%) , SAH 18/446 (4.0%) , TIA 6/446 (1.3%) .Interaction prevalence by event group (pre-specified comparison of ischemic/TIA vs hemorrhagic:Ischemic/TIA (n=387): – PD (bleeding-risk): 130/387 (33.6%) – PK inhibitors (↑ exposure): 37/387 (9.6%) – PK inducers (↓ exposure): 18/387 (4.7%) Hemorrhagic (n=59): – PD (bleeding-risk): 15/59 (25.4%) – PK inhibitors (↑ exposure): 7/59 (11.9%) – PK inducers (↓ exposure): 6/59 (10.2%) PD combinations consistently exceeded PK DDIs overall, driven primarily by acetylsalicylic acid/aspirin and clopidogrel; heparins were less frequent. Among PK interactions, amiodarone predominated as an inhibitor and phenytoin as an inducer. The relative excess of PD DDIs in ischemic/TIA and the higher proportions of PK..."

Clinical • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Contemporary U.S. Practice Patterns Regarding Anticoagulation and LAA Closure in ICH Survivors with Atrial Fibrillation (ISC 2026) - "We used RxNorm codes to identify prescriptions for aspirin and anticoagulant drugs, specifically warfarin, apixaban, dabigatran, or rivaroxaban. In this large, contemporary national U.S. cohort of patients with AF and ICH, approximately half were started on anticoagulation after discharge, and the remainder were mostly treated with aspirin only. Fewer than 1 in 20 patients underwent LAA occlusion, even in recent years. These findings suggest ongoing uncertainty and equipoise between anticoagulant and antiplatelet therapy for secondary stroke prevention in patients with AF and ICH."

Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Sequential delivery of sinigrin and dabigatran by an in situ self-stabilizing dynamic hydrogel attenuates intervertebral disc degeneration. (PubMed, Mater Today Bio) - "Mechanistically, the rapid release of SIN attenuated inflammation by targeting MAPK signalling, while sustained DAB release inhibited inflammation via RELA and promoted extracellular matrix anabolism by activating AMPK. This reconfigurable hydrogel platform offers an innovative strategy for developing next-generation biomaterials that respond to complex disease microenvironments for adaptive therapy."

Journal • Inflammation • Metabolic Disorders • RELA

Pharmacogenomic profiling of ABCB1 and CES1 in atrial fibrillation patients on dabigatran from a multiethnic Malaysian cohort. (PubMed, Sci Rep) - No abstract available

Biomarker • Journal • Atrial Fibrillation • Cardiovascular • ABCB1

Direct Oral Anticoagulant Levels at Time of Elective Surgery. (PubMed, JAMA Netw Open) - "This cohort study (DOAC Level Prior to Incision [DALI]) assessed adult patients prescribed a DOAC (apixaban, dabigatran, or rivaroxaban) for any indication and at any dose, undergoing an elective procedure requiring DOAC interruption between May 27, 2018, and February 25, 2024, at 2 Dutch hospitals. In this cohort study, most patients following the current protocol had DOAC levels less than 30 ng/mL, although the proportion of patients with elevated levels was higher for apixaban. Preoperative DOAC levels were not associated with blood loss during surgery."

Journal

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications. (PubMed, Clin Transl Sci) - "Cohort 3 received an oral solution containing microdoses of dabigatran (P-gp), pitavastatin (OATP1B1), rosuvastatin (BCRP, OATP, and P-gp), atorvastatin (BCRP, OATP, P-gp, and CYP3A4), and midazolam...Steady-state ecopipam administration increased dextromethorphan exposure (> 100-fold); decreased the AUCinf of midazolam, omeprazole, and dabigatran by 44.2%, 44.1%, and 37.9%, respectively; and decreased unconjugated bilirubin (UGT1A1) by 19.5%...There were no changes in caffeine, bupropion, or pitavastatin exposure. Ecopipam is a strong inhibitor of CYP2D6 and weak inducer of CYP3A4, CYP2C19, P-gp, and UGT1A1. Ecopipam did not inhibit CYP3A4, CYP2C19, CYP2B6, CYP1A2, UGT1A1, P-gp, or OATP1B1 and did not induce OATP1B1 or CYP2B6."

Journal • PK/PD data • Movement Disorders • Tourette Syndrome • CYP1A2 • CYP2C19 • CYP3A4 • UGT1A1

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. (PubMed, Clin Transl Sci) - "PBPK model simulations predicted no major change in rosuvastatin, a substrate for OATPs and BCRP, pharmacokinetics when co-administered with dicloxacillin or flucloxacillin. Simulations with dicloxacillin and P-gp substrates dabigatran or digoxin also predicted limited inhibition of P-gp transport."

Journal • PK/PD data • Preclinical • Breast Cancer • Oncology • Solid Tumor • SLCO2B1

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism in Hematologic Malignancies: A Comprehensive Review. (PubMed, Eur J Haematol) - "Direct oral anticoagulants (DOACs), including factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and thrombin inhibitors (dabigatran), have emerged as appealing alternatives due to their ease of use, predictable pharmacokinetics, and reduced monitoring requirements. It emphasizes individualized anticoagulation strategies, highlights existing evidence gaps, and outlines future research priorities, particularly the safe application of DOACs in severe thrombocytopenia and interactions with targeted therapies. Ultimately, tailored anticoagulant approaches are essential to optimizing patient outcomes in this complex patient population."

Journal • Review • Cardiovascular • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Venous Thromboembolism

Urine-based point-of-care detection of direct oral anticoagulant activity in acute stroke-accuracy at anti-Xa thresholds relevant for intravenous thrombolysis. (PubMed, Res Pract Thromb Haemost) - "Factor Xa inhibitors were quantified using drug-specific chromogenic anti-Xa assays; dabigatran activity was measured using Biophen DTI...Urine-based DOAC dipstick testing is a rapid, accurate, and reliable method for detecting anticoagulatory activity in AIS patients, providing a valuable tool to guide acute therapeutic decisions. Future studies are warranted to validate its clinical impact and broader applicability, especially in the emergency setting."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay. (PubMed, Res Pract Thromb Haemost) - "Normal pooled plasma was spiked with therapeutic and supratherapeutic concentrations of apixaban, edoxaban, rivaroxaban, and dabigatran. Activated charcoal-based DOAC removal treatment provides a practical solution to restore assay reliability. These findings support the integration of DOAC removal into anti-FVIII testing protocols for patients on anticoagulant therapy."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Subclinical atrial fibrillation: Implications of recent trials for guideline updates? (PubMed, World J Cardiol) - "Previous randomized trials of direct oral anticoagulants (DOACs) in patients with cryptogenic stroke-NAVIGATE-ESUS (with rivaroxaban) and RE-SPECT ESUS (using dabigatran)-failed to demonstrate superiority over aspirin. More recently, two dedicated studies in SCAF with DOACs have been published: NOAH-AFNET 6 (with edoxaban) and ARTESIA (with apixaban)...For those with high bleeding risk, re-evaluation after optimizing modifiable bleeding risk factors (e.g., concomitant medications, blood pressure control) may help determine eligibility for anticoagulation. Ongoing large-scale DOAC trials will further clarify this contentious issue."

Journal • Review • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • Hypertension

Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring. (PubMed, Front Pharmacol) - "ROR = 4.68, 95% CI: 3.41-6.55), particularly levofloxacin (adj. ROR = 6.12) and ciprofloxacin (adj...No significant signals were found for rivaroxaban, apixaban, or edoxaban...Other DOACs appear safer with FQNs coadministration. For dabigatran patients requiring FQNs, alternative agents or enhanced monitoring should be considered."

Adverse events • Journal • Hematological Disorders

Reduced Versus Full-Dose Direct Oral Anticoagulants for Long-Term Management of Venous Thromboembolism: A Systematic Review. (PubMed, J Clin Med) - " A systematic search of PubMed and the Cochrane Library (January 2010-November 2025) identified randomized trials and one ambispective cohort study evaluating reduced-dose apixaban (2.5 mg BID), rivaroxaban (10 mg OD), dabigatran (110 mg BID), or edoxaban (30 mg OD)...Across trials, reduced-dose DOACs maintained consistently low rates of recurrent VTE: 1.7% in AMPLIFY-EXT versus 8.8% with placebo; 1.2-1.5% in EINSTEIN CHOICE versus 4.4% with aspirin; 2.2% in RENOVE versus 1.8% with full-dose therapy; and 1.3% in HI-PRO versus 10% with placebo... In summary, reduced-dose DOACs appear to offer a favorable balance of safety and efficacy, providing durable protection against recurrence with a lower bleeding burden. These findings support their role as a practical extended-treatment strategy in clinical practice."

Journal • Review • Cardiovascular • Venous Thromboembolism

Dabigatran prevents lipopolysaccharide mediated apoptosis in zebrafish through a thrombin independent mechanism. (PubMed, Shock) - "In summary, we identify several novel small molecules that prevent LPS-induced endotoxemia and show that one such small molecule, dabigatran, exerts a thrombin-independent effect on nitric oxide production and apoptosis. This and the other identified small molecules warrant further exploration in inflammatory conditions including sepsis."

Journal • Infectious Disease • Inflammation • Septic Shock

Temporal Trends in the Use of Direct Oral Anticoagulants Prior to Stroke Admission. (PubMed, J Stroke Cerebrovasc Dis) - "The proportion of patients on DOACs at admission doubled between 2015 and 2023. Patients on DOACs were older, had more comorbidities. Patients with ICH on DOAC prior to admission were more likely to have died during their hospitalization or be discharged to long-term care."

Journal • Cardiovascular • Cerebral Hemorrhage • Ischemic stroke

From Clot Prevention to Kidney Injury: Revisiting Anticoagulant-Related Nephropathy. (PubMed, Kidney Blood Press Res) - "Anticoagulant-related nephropathy (ARN) is a serious and often underdiagnosed complication of anticoagulant therapy, particularly associated with vitamin K antagonists, such as warfarin, and more recently, with direct oral anticoagulants (DOACs), including dabigatran, rivaroxaban, edoxaban, and apixaban. Despite various treatment approaches, ranging from withdrawal of anticoagulation to supportive therapy and corticosteroids, no definitive treatment exists. This review discusses the epidemiology, pathogenesis, diagnosis, and treatment of ARN."

Journal • Review • Acute Kidney Injury • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. (clinicaltrials.gov) - P=N/A | N=500 | Active, not recruiting | Sponsor: Petrovsky National Research Centre of Surgery

New trial • Cardiovascular • Hematological Disorders • Thrombosis

Dabigatran and Edoxaban in the Repair of an Abnormal Cleft in the Right Wall of the Ascending Aorta: A Case Report. (PubMed, Cureus) - "In this case report, linear white (high echo intensity) thrombi extending from the right upper pulmonary vein (RUPV) penetrated the wall of the ascending aorta (AAo), resulting in a cleft in the AAo wall in an area with possible medial degeneration. Additionally, we show that dabigatran and edoxaban partially resolved the linear thrombi and cured the cleft."

Journal • Atherosclerosis • Cardiovascular

DABI-SNAP: Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Emily McDonald | Trial completion date: Jan 2029 ➔ Jan 2030 | Trial primary completion date: Jan 2029 ➔ Jan 2030 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Infectious Disease